Kynam Capital reports 1.54% Viridian (VRDN) stake in Schedule 13G/A filing
Rhea-AI Filing Summary
Kynam Capital Management and related reporting persons filed an amended Schedule 13G/A disclosing a passive ownership stake in Viridian Therapeutics, Inc. As of 12/31/2025, they collectively reported beneficial ownership of 1,470,541 shares of Viridian common stock, representing 1.54% of the outstanding class.
The filing shows Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang each having shared voting and shared dispositive power over these 1,470,541 shares, with no sole voting or dispositive power. The certification states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Viridian.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake in Viridian Therapeutics (VRDN) does Kynam Capital report in this Schedule 13G/A?
Kynam Capital and related filers report beneficial ownership of 1,470,541 Viridian shares, or 1.54% of the common stock. This reflects a relatively small, passive position rather than a controlling stake in the company’s equity.
Which entities are the reporting persons in the Viridian Therapeutics (VRDN) Schedule 13G/A?
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. All three report the same 1,470,541 Viridian shares with shared voting and dispositive power, and no sole authority over the shares.
Does the Kynam Capital Schedule 13G/A indicate an activist intent toward Viridian Therapeutics (VRDN)?
The filing expressly describes the holdings as acquired and held in the ordinary course of business. It states they are not held to change or influence control of Viridian, indicating a passive investment rather than an activist position.
As of what date is Kynam Capital’s Viridian Therapeutics (VRDN) ownership reported?
The ownership information is reported as of 12/31/2025, the date of the event requiring the filing. That date anchors the 1,470,541 Viridian shares and 1.54% beneficial ownership disclosed in this amended Schedule 13G/A.